Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	236	247	258	117	112	383
Revenue Growth (YoY)	67.38%	-4.26%	120.51%	4.46%	-70.76%	391.03%
Gross Profit	236	247	258	117	112	383
Selling, General & Admin	111	110	120	117	104	72
Research & Development	523	523	448	340	288	257
Other Operating Expenses	-	-	20	-	-	-
Total Operating Expenses	634	633	588	457	392	329
Operating Income	-398	-386	-330	-340	-280	54
Interest Income	39	41	52	41	16	1
Interest Expense	-10	-8	-4	-2	-2	-
Total Non-Operating Income (Expense)	29	33	48	39	14	1
Pretax Income	-369	-353	-282	-301	-266	55
Provision for Income Taxes	-	-	1	6	1	2
Net Income	-369	-353	-283	-307	-267	53
Net Income to Common	-369	-353	-283	-307	-267	53
Shares Outstanding (Basic)	114	107	90	74	72	69
Shares Outstanding (Diluted)	114	107	90	74	72	74
Shares Change (YoY)	22.63%	19.20%	21.76%	2.78%	-2.70%	35.04%
EPS (Basic)	-3.23	-3.29	-3.14	-4.15	-3.71	0.76
EPS (Diluted)	-3.23	-3.29	-3.14	-4.15	-3.71	0.71
Shares Outstanding	125.5	125.3	92.2	75.5	72.9	70.78
Free Cash Flow	-489	-484	-176	-330	432	-282
Free Cash Flow Per Share	-4.28	-4.51	-1.95	-4.46	6.00	-3.81
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-168.64%	-156.28%	-127.91%	-290.60%	-250.00%	14.10%
Profit Margin	-156.36%	-142.91%	-109.69%	-262.39%	-238.39%	13.84%
FCF Margin	-207.20%	-195.95%	-68.22%	-282.05%	385.71%	-73.63%
EBITDA	-389	-376	-320	-332	-274	58
EBITDA Margin	-164.83%	-152.23%	-124.03%	-283.76%	-244.64%	15.14%
EBIT	-398	-386	-330	-340	-280	54
EBIT Margin	-168.64%	-156.28%	-127.91%	-290.60%	-250.00%	14.10%
Effective Tax Rate	-	0.00%	-0.35%	-1.99%	-0.38%	3.64%

Updated May 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q